We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

130 hedge funds and large institutions have $341M invested in Sucampo Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 65 increasing their positions, 28 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 28

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

21% more capital invested

Capital invested by funds: $281M → $341M (+$60.3M)

4% more funds holding

Funds holding: 125130 (+5)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less call options, than puts

Call options by funds: $678K | Put options by funds: $696K

Holders
130
Holders Change
+5
Holders Change %
+4%
% of All Funds
3.5%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
27
Increased
65
Reduced
28
Closed
22
Calls
$678K
Puts
$696K
Net Calls
-$18K
Net Calls Change
+$116K
Name Holding Trade Value Shares
Change
Change in
Stake
New York State Common Retirement Fund
76
New York State Common Retirement Fund
New York
$539K +$569K +32,793 New
PCM
77
Piermont Capital Management
Missouri
$538K
AIG
78
American International Group
New York
$503K +$338K +19,494 +175%
IA
79
Icon Advisers
Colorado
$448K +$474K +27,312 New
GF
80
Gerstein Fisher
New York
$446K +$2.2K +127 +0.5%
Jacobs Levy Equity Management
81
Jacobs Levy Equity Management
New Jersey
$424K -$93.6K -5,400 -17%
PPA
82
Parametric Portfolio Associates
Washington
$381K +$10.1K +582 +3%
PCM
83
Prelude Capital Management
New York
$363K -$10.4K -600 -3%
RhumbLine Advisers
84
RhumbLine Advisers
Massachusetts
$363K +$79.2K +4,570 +26%
DekaBank Deutsche Girozentrale
85
DekaBank Deutsche Girozentrale
Germany
$358K +$13.9K +800 +4%
OAM
86
Oberweis Asset Management
Illinois
$348K -$45.1K -2,600 -11%
Swiss National Bank
87
Swiss National Bank
Switzerland
$317K
TI
88
Trexquant Investment
Connecticut
$294K -$1.87M -107,600 -86%
Citigroup
89
Citigroup
New York
$288K +$29.4K +1,693 +11%
EGA
90
Eagle Global Advisors
Texas
$276K
NFA
91
Nationwide Fund Advisors
Ohio
$265K +$53.4K +3,078 +24%
MLICM
92
Metropolitan Life Insurance Company (MetLife)
New York
$262K +$12.9K +745 +5%
Tudor Investment Corp
93
Tudor Investment Corp
Connecticut
$250K +$34.7K +2,000 +15%
Allianz Asset Management
94
Allianz Asset Management
Germany
$242K -$727K -41,950 -74%
QSS
95
Quantitative Systematic Strategies
Florida
$228K +$245K +14,127 New
JWS
96
Juncture Wealth Strategies
Arizona
$219K +$231K +13,351 New
SKK
97
Shepherd Kaplan Krochuk
Massachusetts
$217K +$229K +13,225 New
BJ
98
BlackRock Japan
Japan
$208K -$80.1K -4,618 -27%
CSS
99
Cubist Systematic Strategies
Connecticut
$184K +$18.1K +1,043 +10%
VOYA Investment Management
100
VOYA Investment Management
Georgia
$180K +$190K +10,934 New

SCMP Hedge Fund Activity: Q2 2015 in Review

130 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q2 2015, worth a combined $341M — up 21% from $281M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new SCMP positions and 22 closed out — a net gain of 5 holders — while 65 added to existing stakes and 28 trimmed.

The largest buyer was Invesco, adding an estimated $17.5M. The largest seller was Visium Asset Management, exiting entirely with an estimated $10.9M sold.

  • 130 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q2 2015, up from 125 in Q1 2015.
  • Funds reported $341M of Sucampo Pharmaceuticals, Inc. stock for Q2 2015, up 21% quarter-over-quarter.
  • 27 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q2 2015 and 22 closed out, a net change of +5 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q2 2015 was Invesco, an estimated $17.5M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q2 2015 was Visium Asset Management, an estimated $10.9M sold.

Based on aggregated 13F filings for Q2 2015.